Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents

Pathophysiology of Haemostasis and Thrombosis

Volumn 34, Issue 4-5, 2006, Pages 188-193

  Flight, Simone ^a   Johnson, Lambro ^a   Trabi, Manuela ^a,c   Gaffney, Patrick ^b   Lavin, Martin ^c   De Jersey, John ^a   Masci, Paul ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Aprotinin; Enzyme inhibition; Fibrinolysis; Kallikrein; Plasmin; Textilinin; Thrombelastography

Indexed keywords

ALTEPLASE; ANTIFIBRINOLYTIC AGENT; APROTININ; HEMOSTATIC AGENT; PLASMA KALLIKREIN; PLASMIN; PLASMIN INHIBITOR; Q 8008; RECOMBINANT TEXTILININ 1; SERINE PROTEINASE INHIBITOR; TISSUE KALLIKREIN; TRYPSIN; UNCLASSIFIED DRUG;

BLOOD CLOT LYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; HUMAN; MOLECULAR MODEL; PRIORITY JOURNAL; PSEUDONAJA TEXTILIS; SEQUENCE HOMOLOGY; SNAKE; THROMBOELASTOGRAPHY;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; APROTININ; ELAPID VENOMS; HUMANS; PLASMA KALLIKREIN; PLASMIN; SERINE PROTEINASE INHIBITORS; SNAKE VENOMS; THROMBELASTOGRAPHY; TISSUE KALLIKREINS;

EID: 33646760650     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092421     Document Type: Conference Paper

References (39)

1. Masci PP, Whitaker AN, Sparrow LG, et al: Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model. Blood Coagul Fibrinolysis 2000;11:385-393.
2. Kraut H, Frey E, Werle E: Uber die Inaktivierung des Kallikreins. Hoppe Seylers Z Physiol Chem 1930;192:1-21.
3. Kunitz M, Northrop J: Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor and intibular trypsin compound. J Gen Physiol 1936;19:991-1007.
4. Grzesiak A, Helland R, Smalas AO, Krowarsch D, Dadlez M, Otlewski J: Substitutions at the P(1) position in BPTI strongly affect the association energy with serine proteinases. J Mol Biol 2000;301:205-217.
5. Cierpicki T, Otlewski J: NMR structures of two variants of bovine pancreatic trypsin inhibitor (BPTI) reveal unexpected influence of mutations on protein structure and stability. J Mol Biol 2002;321:647-658.
6. Hoffmann H, Siebeck M, Thetter O, Jochum M, Fritz H: Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv Exp Med Biol 1989;247B:35-42.
7. Fritz H, Wunderer G: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983;33:479-494.
8. Davis R, Whittington R: Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49:954-983.
9. Segal H: Aprotinin: pharmacological reduction of perioperative bleeding. Lancet 2000;355:1289-1290.
10. Longstaff C: Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994;5:537-542.
11. Ray MJ: Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost 1997;78:1021-1026.
12. Dietrich W: Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996;27:50-57.
13. Khan TA, Voisine P, Sandmeyer J, Feng J, Sellke FW: Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg 2005;79:1545-1550.
14. van Oeveren W, Roozendaal KJ: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-797.
15. Aubin F, Javaudin L, Rochcongar P: Case report of aprotinin in Achilles tendinopathies with athletes. J Pharm Clin 1997;16:270-273.
16. Zacharski LR, Hommann M, Kaufmann R: Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma. Expert Rev Cardiovasc Ther 2004;2:777-784.
17. Cumming A: Acute renal failure and sepsis: therapeutic approaches. Nephrol Dial Transplant 1994;9:159-163.
18. Rabito BW: Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr Pharm Des 2003;9:777-787.
19. Chabbat J, Porte P, Tellier M, Steinbuch M: Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 1993;71:205-215.
20. Mojcik CF, Levy JH: Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001;71:745-754.
21. Salooja N, Perry DJ: Thrombelastography. Blood Coagul Fibrinolysis 2001;12:327-337.
22. Royston D: High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992;6:76-100.
23. Lassen M: The estimation of fibrinolytic components by means of the lysis time method. Scand J Clin Lab Invest 1958;10:384-389.
24. Casati V, Bellotti F, Gerli C, Franco A, Oppizzi M, Cossolini M, Calori G, Benussi S, Alfieri O, Torri G: Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesthesiology 2001;94:8-14.
25. Troianos CA, Sypula RW, Lucas DM, D'Amico F, Mathie TB, Desai M, Pasqual RT, Pellegrini RV, Newfeld ML: The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology 1999;91:430-435.
26. Carless PA, Moxey AJ, Stokes BJ, Henry DA: Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomised head-to-head trials. BMC Cardiovasc Disord 2005;5:19.
27. Tanakaa KA, Szlama F, Katoria N, et al: Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res 2005;13:333-339.
28. Ohri SK, Parratt R, White T, et al: A genetically engineered human Kunitz protease inhibitor with increased kallikrein inhibition in an ovine model of cardiopulmonary bypass. Perfusion 2001;16:199-206.
29. Zabel BA, Allen SJ, Kulig P, et al: Chemerin activation by serine proteases of the coagulation, fibrinolytic and inflammatory cascades. J Biol Chem 2005.
30. Sturzebecher J, Schweinitz A, Schmalix WA, Wikstrom P: Synthetic urokinase inhibitors as potential anti-invasive drugs. IDrugs 2001;4:677-683.
31. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P: The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002;277:46932-46939.
32. Jenkins GR, Seiffert D, Parmer RJ, Miles LA: Regulation of plasminogen gene expression by interleukin-6. Blood 1997;89:2394-2403.
33. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I: Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000;30:204-218.
34. Del Rosso M, Fibbi G, Matucci Cerinic M: The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin Exp Rheumatol 1999;17:485-498.
35. Kummer JA, Abbink JJ, de Boer JP, et al: Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-893.
36. Judex MO, Mueller BM: Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 2005;166:645-647.
37. Kawakami M, Kawagoe M, Harigai M, et al: Elevated plasma levels of alpha 2-plasmin inhibitor-plasmin complex in patients with rheumatic diseases. Possible role of fibrinolytic mechanism in vasculitis. Arthritis Rheum 1989;32:1427-1433.
38. Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003;33:275-281.
39. Alfano D, Franco P, Vocca I, et al: The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005;93:205-211.